Analysts Issue Research Notes On Lineage Cell Therapeutics Inc. (LCTX)

0
65
Twitter
Twitter

Lineage Cell Therapeutics Inc. (AMEX:LCTX) finished Wednesday with an addition of $0.01 to close at $1.06, an upside of 0.95 percent. An average of 649,040 shares of common stock have been traded in the last five days. There was a fall of -$0.1400 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 405,425 shares traded, while the 50-day average volume stands at 386,660.

LCTX stock has decreased by -23.74% in the last month. The company shares reached their 1-month lowest point of $1.0300 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $1.02 and a high of $2.64 in 52 weeks. It has reached a new high 1 time so far this year and lost -56.73% or -$1.3900 in price. In spite of this, the price is down -59.85% from the 52-week high.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Insider Transactions

LCTX stock investors should be aware that Lineage Cell Therapeutics Inc. (LCTX) stock had its last reported insider trading activity 0 days ago on Mar 31.

Valuation Metrics

Lineage Cell Therapeutics Inc. (LCTX) stock’s beta is 1.71. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 13.23, the price-to-book (PB) ratio at 2.30, and the price-to-cash flow ratio at 63.85.

Financial Health

The quick ratio of Lineage Cell Therapeutics Inc. for the three months ended June 29 was 3.00, and the current ratio was 3.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $2.92 million compared to revenue of $4.34 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Lineage Cell Therapeutics Inc.’s return on assets was -33.40%.

Earnings Surprise

For the three-month period that ended June 29, Lineage Cell Therapeutics Inc. had $41.6 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$6.07 million in the quarter, while revenues of -$6.76 million were shrunk -28.83%. The analyst consensus anticipated Lineage Cell Therapeutics Inc.’s latest quarter earnings to come in at -$0.04 per share, but it turned out to be -$0.04, a 0.00% surprise. For the quarter, EBITDA amounted to -$5.08 million. Shareholders own equity worth $169.98 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Lineage Cell Therapeutics Inc. (LCTX) price momentum. RSI 9-day as of the close on 28 December was 26.44%, suggesting the stock is oversold, with historical volatility in this time frame at 48.62%.

As of today, LCTX’s price is $1.1080 -11.67% or -$0.1400 from its 5-day moving average. LCTX is currently trading -27.89% lower than its 20-day SMA and -38.01% lower than its 100-day SMA. However, the stock’s current price level is -1.85% below the SMA50 and -15.87% below the SMA200.

The stochastic %K and %D were 5.90% and 8.22%, respectively, and the average true range (ATR) was 0.0950. With the 14-day stochastic at 7.32% and the average true range at 0.0947, the RSI (14) stands at 32.72%. The stock has reached -0.1067 on the 9-day MACD Oscillator while the 14-day reading was at -0.1469.

Analyst Ratings

Robert W. Baird launched coverage on Lineage Cell Therapeutics Inc. (AMEX: LCTX) in its analyst report released on November 02, 2022. The firm assigned the stock an Outperform rating.

LEAVE A REPLY

Please enter your comment!
Please enter your name here